LNTHNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Lantheus Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$99.92+0.22 (+0.22%)
Close on Oct 19, 2026
- Market cap
- $6.75B
- P/E (TTM)
- 24.2
- Dividend yield
- –
Lantheus Holdings, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $376.93M | $369.85M | $389.42M | $376.69M | $374.55M | $366.92M | $388.11M | $374.60M | $392.76M | $369.31M | $337.22M | $319.51M | 97.1% | +0.6% |
| PYLARIFY | $240.37M | $240.92M | $240.20M | $240.62M | $250.64M | $257.65M | $265.95M | $259.76M | $273.26M | $258.87M | $229.88M | $215.43M | 61.9% | -4.1% |
| Total oncology | $240.37M | $240.92M | – | – | $250.64M | $257.65M | – | – | – | – | – | – | 61.9% | -4.1% |
| DEFINITY | $88.28M | $84.63M | $85.31M | $81.79M | $83.94M | $79.21M | $86.16M | $76.97M | $78.10M | $76.56M | $73.08M | $67.34M | 22.7% | +5.2% |
| Total cardiology | $88.28M | $84.63M | – | – | $83.94M | $79.21M | – | – | – | – | – | – | 22.7% | +5.2% |
| Neuraceq | $39.62M | $35.44M | $31.01M | $20.44M | $0 | $0 | $0 | $0 | – | – | – | – | 10.2% | – |
| Total neurology | $39.62M | $35.44M | – | – | $0 | $0 | – | – | – | – | – | – | 10.2% | – |
| Strategic partnerships and other revenue | $19.92M | $16.34M | $23.34M | $13.71M | $11.59M | $10.75M | $7.70M | $15.25M | $8.73M | $6.51M | $22.79M | $7.32M | 5.1% | +71.9% |
| License and royalty revenues | $11.25M | $7.48M | $17.37M | $7.33M | $3.50M | $5.85M | $3.00M | $4.13M | $1.34M | $662.00K | $16.78M | $438.00K | 2.9% | +221.5% |
| SPECT | $0 | $0 | – | – | $31.87M | $25.15M | – | – | – | – | – | – | 0.0% | -100.0% |
| Techne Lite | – | – | $20.98M | $21.13M | $24.98M | $19.71M | $25.11M | $20.48M | $28.19M | $21.71M | $21.52M | $23.27M | – | – |
| Total precision diagnostics | – | – | $143.25M | $129.69M | $115.81M | $104.36M | $117.46M | $103.73M | $112.11M | $104.21M | $100.58M | $96.35M | – | – |
| Total radiopharmaceutical oncology | – | – | $240.20M | $240.62M | $250.64M | $257.65M | $265.95M | $259.76M | $273.26M | $259.25M | $230.63M | $216.28M | – | – |
| Other precision diagnostics | – | – | $5.94M | $6.34M | $6.89M | $5.44M | $6.19M | $6.28M | $5.83M | $5.93M | $5.98M | $5.74M | – | – |
| Other radiopharmaceutical oncology | – | – | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $384.00K | $747.00K | $848.00K | – | – |
| License And Royalty Revenues Sales Based Milestone Payment | – | – | – | $0 | $0 | $0 | – | – | – | $0 | $15.00M | – | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $368.29M | $354.43M | – | – | $356.30M | $357.76M | – | – | – | – | – | – | 94.9% | +3.4% |
| Rest of world | $19.89M | $22.91M | – | – | $21.74M | $15.01M | – | – | – | – | – | – | 5.1% | -8.5% |
From the segment and revenue-disaggregation notes of Lantheus's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.